BP CYT3 (Clenbuterol, Yohimbine and T3 Combo)

BP CYT3 is a research-grade tri-compound preparation combining clenbuterol HCl (β2-adrenergic agonist), yohimbine HCl (α2-adrenergic antagonist) and liothyronine sodium / T3 (thyroid hormone receptor ligand) in a single unit. It is intended strictly for in vitro thermogenic and lipolytic comparative studies in South African laboratories. An analogous CTY3 specification published in 2022 lists 50 µg clenbuterol, 5.5 mg yohimbine and 25 µg T3 per tablet, an approximate 1 : 2.4 : 0.7 molar ratio. No 2024–2026 peer-reviewed in vitro study using all three compounds in one preparation has been published, so the rationale below is reconstructed receptor-by-receptor. South African procurement of a clenbuterol yohimbine T3 combo falls under SAHPRA (South African Health Products Regulatory Authority) and the Medicines and Related Substances Act 101 of 1965, with no local carve-out for "research chemicals".

This article covers what BP CYT3 is, how its three active compounds work at the cellular level, why researchers choose a combined preparation over separate stocks, and how to source it legally in South Africa.

Key Takeaways

• BP CYT3 combines three non-overlapping receptor targets: β2-adrenergic (clenbuterol), α2-adrenergic (yohimbine), and thyroid hormone (T3) signalling
• A fixed-ratio blend eliminates pipetting variance across dose-response assays compared to three separate stocks
• Clenbuterol drives lipolysis via cAMP and HSL phosphorylation; yohimbine removes the α2-mediated brake on that signal; T3 engages a separate genomic axis over hours
• South African law treats all three actives as scheduled substances under the Medicines Act; no deregulated "research chemical" category exists
• Institutional procurement requires SAHPRA compliance, ethics approval where applicable, and controlled-substance record-keeping

What Is BP CYT3? A Quick Definition

BP CYT3 is a single-unit research preparation supplied by Body Pharm containing three thermogenic actives: clenbuterol HCl, yohimbine HCl and liothyronine sodium (T3). It is co-formulated for in vitro lipolytic and metabolic comparative studies in South African laboratories, not for human or veterinary administration. The "CYT3" designation marks it as a tri-compound blend, distinguishing it from simpler two-agent thermogenic preparations such as clenbuterol+T3 or clenbuterol+yohimbine.

Format and what distinguishes it from single-compound stock

Unlike three separately weighed reference standards, BP CYT3 delivers a fixed clenbuterol:yohimbine:T3 ratio per unit. This eliminates per-experiment compounding steps when running standardised receptor-panel assays. The analogous 2022 AM Helios CTY3 sheet specifies 50 µg clenbuterol, 5.5 mg yohimbine and 25 µg T3 per tablet as a reference configuration for this class of blend.

Researchers needing the isolated β2 agonist rather than the triad can work from the BP Clenbuterol 40 single-compound preparation, or compare format options across the broader clenbuterol research preparations range.

The Three Active Compounds: Roles and Receptor Targets

BP CYT3 combines three agents that hit three pharmacologically non-overlapping targets: a β2-adrenergic agonist (clenbuterol), an α2-adrenergic antagonist (yohimbine), and a nuclear thyroid hormone receptor agonist (T3). For assay design, this matters because each compound can be probed, blocked or substituted independently without disrupting the other two signalling arms, which makes the blend useful for factorial in vitro comparisons against single-agent controls.

Clenbuterol: β2-Adrenergic Agonism

Clenbuterol is a long-acting selective β2-adrenergic receptor agonist that drives lipolysis via the canonical Gs → adenylyl cyclase → cAMP (cyclic adenosine monophosphate) → PKA (protein kinase A) → hormone-sensitive lipase (HSL) phosphorylation cascade. Phosphorylated HSL translocates to the lipid droplet surface and hydrolyses triacylglycerol, releasing non-esterified fatty acids into the culture medium where they can be quantified as a downstream readout in adipocyte models.

Selectivity at β2 over β1 is why clenbuterol is preferred to non-selective agonists like isoprenaline in cell-line work where cardiomyocyte β1 confounding must be minimised. That selectivity ratio is not absolute, and β1 cross-activation rises with concentration. In skeletal muscle cultures, β2-AR (β2-adrenergic receptor) signalling has also been studied for hypertrophic effects via Akt/mTOR crosstalk, independent of the lipolytic axis.

Clenbuterol's plasma half-life of roughly 26 to 36 hours is far longer than adrenaline's seconds-scale lifetime. This makes it useful for sustained receptor occupancy protocols where repeated dosing of endogenous catecholamines would be impractical. Researchers needing the unblended preparation can compare against BP Clenbuterol 40 within the broader clenbuterol research preparations catalogue.

Yohimbine: α2-Adrenergic Antagonism

Yohimbine is included to neutralise the α2-adrenergic brake on lipolysis that clenbuterol cannot reach. α2-ARs (α2-adrenergic receptors) couple to Gi, inhibiting adenylyl cyclase and suppressing the same cAMP pool that β2 agonism elevates. Unopposed β2 activation in α2-rich depots produces a smaller net lipolytic signal than the receptor count alone would predict. Yohimbine competitively antagonises α2A/α2C subtypes, removing that inhibitory tone.

The relevance to comparative metabolic study design lies in regional α2-AR density. Subcutaneous adipocytes, particularly gluteofemoral and lower-abdominal depots, express markedly higher α2:β ratios than visceral or omental depots, a difference characterised in human adipose pharmacology from the late 1980s onwards. Comparing isolated clenbuterol against the CYT3 blend across depot-matched primary cultures therefore isolates an additive, not redundant, mechanism. Researchers running the β2-only arm can source BP Clenbuterol 40 from the wider clenbuterol research preparations catalogue.

T3 (Triiodothyronine): Thyroid Receptor Agonism

T3 contributes a genomic axis that neither clenbuterol nor yohimbine can engage. Liothyronine binds nuclear thyroid hormone receptors TRα1 and TRβ1, recruiting coactivators to thyroid response elements and altering transcription of metabolic genes over hours, not seconds. This places T3 on a fundamentally different timescale from the membrane-receptor cAMP signalling driven by β2 agonism and α2 antagonism. The CYT3 configuration treats it as a third, non-redundant pathway rather than an amplifier of the adrenergic arm.

The transcriptional targets most relevant to comparative metabolic study design include UCP1 (uncoupling protein 1) in brown adipocyte models, driving mitochondrial uncoupling and proton leak; UCP3 in skeletal myocyte models; SERCA isoforms governing futile Ca²⁺ cycling; PGC-1α-linked mitochondrial biogenesis markers; and Na+/K+-ATPase subunits contributing to basal oxygen consumption.

TRβ-selective agonism has become a focused area of metabolic pharmacology in the 2023–2026 literature because TRβ predominates in liver and adipose while TRα drives cardiac chronotropy. Researchers comparing CYT3 against TRβ-selective tool compounds in vitro can dissect which downstream readouts are receptor-subtype dependent.

Why a Combined Preparation? Research Design Rationale

A pre-blended CYT3 stock is chosen when the combined β2 + α2 + TR signal is itself the experimental variable, not the individual contribution of each compound. Fixing the clenbuterol:yohimbine:T3 molar ratio at source eliminates one degree of pipetting variance across a dose-response matrix and removes the cumulative dilution error that compounds when three separate stocks are serially diluted into the same well.

In a practical 96-well adipocyte lipolysis assay, a single CYT3 stock generates an 8-point dilution series with one set of tip changes. The same series built from three independent stocks of clenbuterol HCl, yohimbine HCl and liothyronine sodium requires 24 transfers and three independent concentration verifications. For comparative work where one plate reads CYT3 against a TRβ-selective tool compound or against vehicle, the fixed-ratio blend functions as a single test article with a defined composition profile reportedly modelled on earlier oral CTY3 configurations (50 µg clenbuterol, 5.5 mg yohimbine, 25 µg T3 per unit).

Separate compounds remain preferable when isolating a single receptor arm, running Schild analyses, or titrating one component against a fixed background of the other two. For single-pathway β2 work, researchers should reach for the standalone BP Clenbuterol 40 preparation or browse the broader clenbuterol research preparations catalogue rather than deconvolving CYT3 post hoc.

BP CYT3 in the Context of Metabolic Research Chemicals in 2026

CYT3 occupies the small-molecule adrenergic/thyroid corner of the South African metabolic research chemical toolkit, distinct from the peptide preparations that dominate growth hormone and incretin pathway work. Its three actives converge on β2-adrenergic, α2-adrenergic and nuclear thyroid receptor targets, whereas the peptide modulators stocked alongside it act upstream of, or entirely outside, catecholamine signalling.

A well-designed comparative metabolic programme in 2025–2026 typically runs CYT3 against mechanistically orthogonal preparations rather than treating them as substitutes. AOD-9604, a synthetic fragment of the C-terminus of human growth hormone, models lipolysis through a GH-fragment pathway that does not engage adrenergic receptors. Tesamorelin, a GHRH (growth hormone-releasing hormone) analogue, is used in visceral adiposity models where endogenous GH pulsatility is the variable of interest. Tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide)/GLP-1 (glucagon-like peptide-1) agonist, addresses insulin sensitisation and incretin signalling, again with no direct β2, α2 or TR involvement.

That mechanistic separation is the point. A plate that reads CYT3-driven cAMP elevation in 3T3-L1 adipocytes against an AOD-9604 arm, a Tesamorelin arm and a vehicle control isolates which lipolytic readouts are catecholamine-dependent and which are not. The triad blend therefore functions as the adrenergic/thyroid reference article in a multi-pathway design, not as a replacement for peptide-based tools.

Where CYT3 sits relative to single-compound clenbuterol stocks

For researchers who need only the β2 arm, the standalone BP Clenbuterol 40 preparation is the cleaner choice. The broader clenbuterol research preparations category covers adjacent single-API (active pharmaceutical ingredient) formats. CYT3 is reserved for designs where the combined β2 + α2 + TR signal is itself the test condition.

Regulatory and Safety Context for South African Researchers

BP CYT3 is supplied strictly as a research chemical for in vitro and laboratory use only, and is not for human or veterinary consumption under any framing. In South Africa, both clenbuterol hydrochloride and liothyronine sodium (T3) are Schedule 4 substances under the Medicines and Related Substances Act 101 of 1965 (as amended), regulated by SAHPRA. Procurement, storage and disposal of these actives by an institutional laboratory therefore sit inside the same legal framework that applies to any unregistered Schedule 4 API, including Section 21 considerations where applicable.

Yohimbine's position is less cleanly documented in the public SAHPRA registers. No 2024–2026 Government Gazette amendment descheduling yohimbine could be located at the time of writing. The defensible working assumption for a South African facility is to treat yohimbine HCl as a regulated active pharmaceutical ingredient subject to Medicines Act controls. Verify the current schedule entry in the latest Gazette before placing an order.

South African law does not recognise a separate, deregulated "research chemical" category as of 2026. Institutional biosafety sign-off, ethics committee approval where the protocol requires it, and standard controlled-substance record-keeping apply to CYT3 exactly as they would to the standalone BP Clenbuterol 40 preparation or any other item in the clenbuterol research preparations range.

Sourcing BP CYT3 in South Africa: What to Look For

JCSG.org supplies BP CYT3 as a research preparation for in vitro use. The quality markers worth checking before placing an order are the same ones that apply to any blended thermogenic research chemical:

• A batch-specific certificate of analysis (CoA) issued against the specific lot in the vial
• HPLC (high-performance liquid chromatography) purity data reported separately for each of the three actives, not a single combined figure
• Traceable batch numbering linking the CoA to the physical unit
• Storage and stability statements appropriate to liothyronine, which is the most labile of the three
• A research-grade purity benchmark of ≥98% by HPLC for the individual synthetic actives

No Body Pharm-issued CoA for the CYT3 blend specifically could be independently located at the time of writing. Researchers should request the current batch document directly from the supplier and verify it against an in-house reference standard where one is available.

For South African laboratories ordering online, tracked shipping is the practical baseline. Discreet packaging, a working tracking number routed through a domestic courier, and a secure checkout that issues a tax invoice in ZAR all matter for institutional record-keeping under the Medicines Act framework outlined above. Live pricing for BP CYT3 is listed on the product page itself rather than reproduced here, since vendor pricing on research chemicals shifts with batch and exchange-rate cycles.

Researchers who need the standalone compound can compare specifications against BP Clenbuterol 40, or browse the full clenbuterol research preparations category. To proceed, view BP CYT3 availability, current CoA documentation and ZAR pricing on the JCSG.org catalogue, then route the order through your institution's controlled-substance procurement workflow.

Frequently Asked Questions